Genital lesions are not rare in psoriasis; however, often overlooked is their severe impact on the patient’s QoL [2,3]. Psoriasis in this location is seen as especially embarrassing and is, moreover, often mistaken for a sexually transmitted disease .
A substantial proportion of patients experiences increased problems after sexual activity. In an observational, multicentre study of 354 participants, 87% reported itch, 39% pain, 42% dyspareunia, 32% a worsening of their genital psoriasis after intercourse, and 43% a decreased frequency of intercourse .
The current Phase 3b randomised controlled trial by Dr Jennifer Cather of the Aesthetics Center in Dallas and her colleagues therefore investigated whether treatment of genital psoriasis with the IL-17 blocker ixekizumab has a positive influence on the sexual activity of patients . 149 participants were randomised to receive either a placebo over 12 weeks or 80 mg of ixekizumab subcutaneous every two weeks aft...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Intralesional cryosurgery and itching in psoriasis Next Article
Living in the golden age of psoriasis and atopic dermatitis therapies »
Table of Contents: AAD 2018
Psoriasis: an update
What's hot in atopic dermatitis
Pearls of the posters
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.